VBI Vaccines Valuation
Based on Macroaxis valuation methodology, the entity cannot be evaluated at this time. VBI Vaccines current Real Value cannot be determined due to lack of data. The regular price of VBI Vaccines is $0.0. Our model measures the value of VBI Vaccines from examining the entity fundamentals such as Shares Outstanding of 28.68 M, return on equity of -4.2, and Return On Asset of -0.29 as well as evaluating its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that VBI Vaccines' price fluctuation is out of control at this time. Calculation of the real value of VBI Vaccines is based on 3 months time horizon. Increasing VBI Vaccines' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the VBI stock is determined by what a typical buyer is willing to pay for full or partial control of VBI Vaccines. Since VBI Vaccines is currently traded on the exchange, buyers and sellers on that exchange determine the market value of VBI Stock. However, VBI Vaccines' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0 | Real 0.0 | Hype 0.0 |
The intrinsic value of VBI Vaccines' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence VBI Vaccines' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of VBI Vaccines helps investors to forecast how VBI stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of VBI Vaccines more accurately as focusing exclusively on VBI Vaccines' fundamentals will not take into account other important factors: VBI Vaccines Total Value Analysis
VBI Vaccines is at this time forecasted to have valuation of 38.92 M with market capitalization of 1.87 M, debt of 53.04 M, and cash on hands of 82.41 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the VBI Vaccines fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
38.92 M | 1.87 M | 53.04 M | 82.41 M |
VBI Vaccines Investor Information
The company has Price to Book (P/B) ratio of 1.24. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. VBI Vaccines recorded a loss per share of 3.54. The entity last dividend was issued on the 28th of December 2012. The firm had 1:30 split on the 12th of April 2023. Based on the key indicators related to VBI Vaccines' liquidity, profitability, solvency, and operating efficiency, VBI Vaccines is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.VBI Vaccines Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. VBI Vaccines has an asset utilization ratio of 9.98 percent. This indicates that the Company is making $0.0998 for each dollar of assets. An increasing asset utilization means that VBI Vaccines is more efficient with each dollar of assets it utilizes for everyday operations.VBI Vaccines Ownership Allocation
VBI Vaccines shows a total of 28.68 Million outstanding shares. VBI Vaccines has 6.76 % of its outstanding shares held by insiders and 13.0 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the entity is less than the current market value, you may not be able to make money on it.VBI Vaccines Profitability Analysis
The company reported the previous year's revenue of 8.68 M. Net Loss for the year was (92.84 M) with loss before overhead, payroll, taxes, and interest of (10.19 M).About VBI Vaccines Valuation
Our relative valuation model uses a comparative analysis of VBI Vaccines. We calculate exposure to VBI Vaccines's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of VBI Vaccines's related companies.VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts. Vbi Vaccines operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 149 people.
VBI Vaccines Growth Indicators
Investing in growth stocks can be very risky. If the company such as VBI Vaccines does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 15.6 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in VBI Stock
If you are still planning to invest in VBI Vaccines check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the VBI Vaccines' history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |